| Filed On | Filing |
|---|---|
| 22 Oct 2026 |
8-K: Regulation FD Disclosure
Patient advocacy initiative expands its reach with a nationally recognized voice on health, resilience and informed treatment decisions |
| 14 Oct 2026 |
8-K: Regulation FD Disclosure
TULSA Abstracts at the 15th Interventional MRI Symposium Strengthen Real-World Evidence, Clinical Differentiation, and Platform Expansion Opportunity |
| 09 Oct 2026 |
8-K: Regulation FD Disclosure
Collaboration will educate physicians and prostate cancer centers on the complementary roles of Telix’s PSMA-PET molecular imaging technologies and Profound’s MRI-guided TULSA-PRO® |
| 07 Oct 2026 |
8-K: Results of Operations and Financial Condition
Anticipates Q3-2026 revenue of $9.8 million to $10.0 million, exceeding Bloomberg analyst consensus by approximately 45% to 47% |
| 04 Sep 2026 | 8-K: Regulation FD Disclosure |
| 03 Sep 2026 | 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure |
| 17 Aug 2026 | 8-K: Regulation FD Disclosure |
| 17 Aug 2026 | 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure |
| 13 Aug 2026 | 8-K: Regulation FD Disclosure |
| 06 Aug 2026 | 8-K: Results of Operations and Financial Condition |
| 24 Jul 2026 | 8-K: Regulation FD Disclosure |
| 16 Jul 2026 | 8-K: Regulation FD Disclosure |
| 15 Jul 2026 | 8-K: Regulation FD Disclosure |
| 15 May 2026 | 8-K: Submission of Matters to a Vote of Security Holders |
| 14 May 2026 | 8-K: Regulation FD Disclosure |
| 07 May 2026 | 8-K: Results of Operations and Financial Condition |
| 16 Apr 2026 | 8-K: Regulation FD Disclosure |
| 14 Apr 2026 | 8-K: Regulation FD Disclosure |
| 01 Apr 2026 | 8-K: Regulation FD Disclosure |
| 27 Mar 2026 | 8-K: Regulation FD Disclosure |
Loading...
